We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Amphotericin B deoxycholate for relapse visceral leishmaniasis in Bangladesh: a cross-sectional study.
- Authors
Hasnain, Md Golam; Nath, Proggananda; Maruf, Shomik; Nabi, Shah Golam; Hossain, A. F. M. Akhtar; Ahmed, Be-Nazir; Mondal, Dinesh; Basher, Ariful
- Abstract
Objective: Based on studies in India (as there was no studies from outside India) amphotericin B deoxycholate has been considered as a backup drug for treatment of visceral leishmaniasis. However, treatment response and adverse effect to anti-leishmanial drugs may vary across different populations and in Bangladesh the effect to amphotericin B deoxycholate for treatment of visceral leishmaniasis is still unknown. Therefore, there is a need to explore cure rate and adverse effects to amphotericin B deoxycholate to justify its use on visceral leishmaniasis patients in Bangladesh. Result: Here we report 34 visceral leishmaniasis patients who received treatment with amphotericin B deoxycholate in the Surya Kanta Kala-azar Research Centre from December 2011 to June 2015. The dose of the treatment was 1 mg/kg body weight for 15 days followed up until 12 months after treatment. Response to amphotericin B deoxycholate treatment was excellent as all 34 patients achieved a final cure. Hypokalaemia (47%), shivering (47%), vomiting (35%) and acidity (15%) were most common adverse events. However, we did not observe any serious adverse events. Amphotericin B deoxycholate for relapse visceral leishmaniasis was found to be highly effective and safe. Our study justified to include amphotericin B deoxycholate as a second line drug for visceral leishmaniasis in Bangladesh.
- Subjects
AMPHOTERICIN B; VISCERAL leishmaniasis; DISEASE relapse; EPIDEMIOLOGY; HYPOKALEMIA
- Publication
BMC Research Notes, 2018, Vol 11, Issue 1, pN.PAG
- ISSN
1756-0500
- Publication type
Article
- DOI
10.1186/s13104-018-4036-8